Lobectomy Induces Exercise-Induced Pulmonary Hypertension and Effort Intolerance Compared With Sublobar Resection [0.03%]
肺段切除与肺叶切除术后运动诱发的肺动脉高压和运动不耐受的对比研究
Atsushi Kamigaichi,Yasuhiro Tsutani,Akane Tsuchiya et al.
Atsushi Kamigaichi et al.
Introduction: The rationale underlying the benefits of the parenchyma-preserving nature of sublobar resection (SR) compared with lobectomy remains unclear. This study aimed to assess postoperative changes in cardiopulmona...
Tobacco Control and Smoking Cessation-Related Content in Oncology Meetings: A Systematic Scoping Review [0.03%]
肿瘤学会议中的烟草控制和戒烟相关内容系统综述研究
Sun Choi,Monisha Chawla,Payton Catherwood et al.
Sun Choi et al.
Introduction: Despite the importance of smoking cessation in cancer care, it remains unclear how much tobacco control and smoking-related content (TCSCR) is included in major oncology meetings. Developing an understanding...
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLC [0.03%]
阿特珠单抗联合化疗和帕博利尤单抗联合化疗治疗老年NSCLC患者的多中心回顾性真实世界研究
Kensuke Kanaoka,Kinnosuke Matsumoto,Takayuki Shiroyama et al.
Kensuke Kanaoka et al.
Introduction: Evidence of immune checkpoint inhibitors (ICIs) combined with chemotherapy for older patients with NSCLC is limited. This real-world study compared the efficacy and safety of atezolizumab plus chemotherapy (...
Provider Behavioral Determinants and Preferences for Lung Cancer Screening Implementation: A Brief Report [0.03%]
提供者行为决定因素和肺癌筛查实施偏好：简短报告
Jennifer A Lewis,Lauren R Samuels,Lucy B Spalluto et al.
Jennifer A Lewis et al.
Introduction: Implementation of lung cancer screening is suboptimal. Understanding health care provider preferences and behavior is important for implementation. In this work, provider preferences for lung cancer screenin...
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431] [0.03%]
"帕博利珠单抗联合化疗与单纯化疗治疗转移性非小细胞肺癌的组织肿瘤突变负荷和突变状态及其临床结局"[JTO临床癌症研究报告第4卷第1期：100431]的勘误表
Marina C Garassino,Shirish Gadgeel,Silvia Novello et al.
Marina C Garassino et al.
[This corrects the article DOI: 10.1016/j.jtocrr.2022.100431.]. © 2025 by the International Association for the Study of Lung Cancer.
Published Erratum
JTO clinical and research reports. 2025 Sep 2;6(10):100892. DOI:10.1016/j.jtocrr.2025.100892 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC [0.03%]
一项比较DOSTARLIMAB联合化疗与PEMBROLIZUMAB联合化疗治疗转移性非鳞NSCLC的II期随机试验PERLA的长期生存分析
Sun Min Lim,Ana Laura Ortega Granados,Gustavo Dix Junqueira Pinto et al.
Sun Min Lim et al.
Introduction: PERLA is a global, double-blind, phase II trial comparing anti-programmed cell death protein 1 antibodies, dostarlimab, and pembrolizumab in combination with chemotherapy (D+CT and P+CT, respectively) in pat...
Durable Response to Lenvatinib in Platinum-Refractory Metastatic High-Grade Thymic Mucoepidermoid Carcinoma: A Case Report [0.03%]
仑伐替尼治疗复发性铂类药物耐药的高分化黏膜样胸腺癌1例报告
Noa Amin,Thanika Ketpueak,Simon Jordan et al.
Noa Amin et al.
Thymic mucoepidermoid carcinoma (MEC) is a rare thymic carcinoma subtype. Current metastatic thymic carcinoma guidelines recommend first-line platinum-based chemotherapy. However, evidence suggests that MECs, including those of the lung and...
Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study [0.03%]
Durvalumab联合或不联合Tremelimumab与同期放化疗对比在局限期小细胞肺癌中的疗效：I期CLOVER研究结果
Byoung Chul Cho,Myung-Ju Ahn,Makoto Nishio et al.
Byoung Chul Cho et al.
Introduction: The phase 1 CLOVER study (NCT03509012) evaluated durvalumab with or without tremelimumab in combination with concurrent chemoradiotherapy (cCRT) in patients with advanced solid tumors; here, we report findin...
What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer? [0.03%]
小细胞肺癌和大细胞神经内分泌癌的诊断与治疗展望几何？
Sun Min Lim,Joo Sung Gabriel Shim,Hyo Sup Shim et al.
Sun Min Lim et al.
SCLC is a high-grade neuroendocrine malignancy associated with poor prognosis, comprising 15% of lung cancer cases globally. Advances in genetic profiling have revealed that SCLC is a molecularly heterogeneous disease, categorized into subt...
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 [0.03%]
曲妥珠单抗拉帕坦辛治疗高表达或中度表达CEACAM5的非鳞状NSCLC患者的安全性、药代动力学和抗肿瘤活性评估
Anas Gazzah,Charles Ricordel,Antoine Italiano et al.
Anas Gazzah et al.
Introduction: Tusamitamab ravtansine is an antibody-drug conjugate targeting cells expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with a maytansinoid payload, DM4. This phase 1b dose-expans...